Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.67−0.05 (-7.21%)
Close on Nov 19, 2026Market cap $61.88MP/E –Yield –
Anavex Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Anavex Life Sciences's operating income for the twelve months ending Jun 30, 2026 was -$17.37M. For fiscal 2025 it was -$51.41M. The highest annual figure on record is -$2.14M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$51.41M | – |
| FY2024 | Sep 30, 2024 | -$52.88M | – |
| FY2023 | Sep 30, 2023 | -$55.76M | – |
| FY2022 | Sep 30, 2022 | -$50.99M | – |
| FY2021 | Sep 30, 2021 | -$42.00M | – |
| FY2020 | Sep 30, 2020 | -$31.09M | – |
| FY2014 | Sep 30, 2014 | -$2.97M | – |
| FY2013 | Sep 30, 2013 | -$2.14M | – |
| FY2012 | Sep 30, 2012 | -$4.32M | – |
| FY2011 | Sep 30, 2011 | -$6.18M | – |
| FY2010 | Sep 30, 2010 | -$5.65M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $6.74M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$6.48M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$6.78M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$10.84M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$14.46M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$12.51M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$13.59M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$14.27M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$14.60M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$12.62M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$11.38M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$12.66M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$13.53M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$14.19M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$15.38M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$15.28M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$12.46M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$11.52M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$11.72M | – |
See a number that looks wrong?